佛慈制药：公司2025年前三季度实现营业收入6.24亿元

Core Viewpoint - 佛慈制药 reported significant financial performance improvements for the first three quarters of 2025, highlighting strong revenue growth and cash flow generation [2]. Financial Performance - The company achieved an operating revenue of 624 million yuan for the first three quarters of 2025 [2]. - The net profit attributable to shareholders reached 38.08 million yuan [2]. - The net cash flow generated from operating activities was 93.51 million yuan, reflecting a year-on-year increase of 677.92% [2].